Background-Drug-eluting stents significantly improved angiographic and clinical outcomes compared with bare metal stents in diabetic patients. However, a comparison of everolimus-eluting stents and sirolimus-eluting stents in diabetic patients has not been evaluated. Therefore we compared effectiveness of everolimus-eluting stents and sirolimus-eluting stents in patients with diabetes mellitus. Methods and Results-This prospective, multicenter, randomized study compared everolimus-eluting stent (nϭ149) and sirolimus-eluting stent (nϭ151) implantation in diabetic patients. The primary end point was noninferiority of angiographic in-segment late loss at 8 months. Clinical events were also monitored for at least 12 months. Everolimus-eluting stents were noninferior to sirolimus-eluting stents for 8-month in-segment late loss (0. 
D
iabetic patients often present unfavorable coronary anatomy with small and/or diffusely diseased vessels 1 and exhibit exaggerated neointimal hyperplasia after bare metal stent implantation compared with nondiabetics. 2 Although drug-eluting stent (DES) implantation significantly reduced the neointimal hyperplasia and angiographic restenosis compared with bare metal stents in diabetic patients, 3 the presence of diabetes mellitus (DM) continues to be associated with an increased risk of restenosis and unfavorable clinical outcomes in the era of DES. 4, 5 Recently, the relative efficacies of sirolimus-eluting stent (SES) and paclitaxel-eluting stent (PES) in patients with DM have been evaluated in randomized, registry, and meta-analysis studies, 6 -10 which found SES to have promising efficacy compared with PES in diabetic patients. Recently, everolimus-eluting stents (EES) also showed superior efficacy over PES in large randomized trials. [11] [12] [13] [14] In A Clinical Evaluation of the XIENCE V Everolimus-Eluting Coronary Stent System in the Treatment of Patients With De Novo Coronary Artery Lesions (SPIRIT) III and IV subgroup analysis, no significant differences were observed between EES and PES among diabetic patients, and a significant interaction was noted between stent type and event-free survival. [13] [14] [15] However, it is unclear whether there are differences in efficacy and safety between EES and SES in diabetic patients. This prospective randomized study compared angiographic and clinical outcomes of EES and SES in diabetic patients.
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Methods
Patient Selection
This prospective randomized study included 300 patients between 18 years and 75 years of age with coronary artery disease. The study involved 15 cardiac centers in Korea between June 2008 and August 2009. Patients were considered eligible if they had DM with either stable angina or an acute coronary syndrome and had at least 1 coronary lesion (defined as stenosis of Ͼ50% and visual reference diameter Ն2.5 mm) suitable for stent implantation. Patients were excluded if they had contraindication to aspirin or clopidogrel; unprotected left main disease (diameter stenosis Ն50% by visual estimate); graft vessel disease; left ventricular ejection fraction Ͻ30%; recent history of hematologic disease or leukocyte count Ͻ3000 per 1 mm 3 and/or platelet count Ͻ100 000 per 1 mm 3 ; hepatic dysfunction with aspartate aminotransferase or alanine aminotransferase Ն3 times the upper normal reference limit; history of renal dysfunction or serum creatinine level Ն2.0 mg/dL; serious noncardiac comorbid disease with a life expectancy Ͻ1 year; primary angioplasty for acute myocardial infarction (MI) within 24 hours; or inability to follow the protocol. In patients with multiple lesions who fulfilled the inclusion and exclusion criteria, the first stented lesion was considered the target lesion. The institutional review board at each participating center approved the protocol. All patients provided written informed consent.
Randomization and Procedures
Once the guidewire had crossed the target lesion, patients were randomly assigned in a 1:1 ratio to EES (Xience V, Abbott Vascular) or SES (Cypher Select and Cypher Select Plus, Cordis, Johnson & Johnson) implantation through the use of an interactive Web response system. The allocation sequence was computer generated, stratified according to participating center, and blocked with block sizes of 4 and 6 that varied randomly. Random assignments were stratified according to participation sites. Before or during the procedure, all patients received at least 100 mg aspirin and a 300-to 600-mg loading dose of clopidogrel. Heparin was administered throughout the procedure to maintain an activated clotting time of Ն250 seconds. Administration of glycoprotein IIb/IIIa inhibitors was at the discretion of the operator. After the procedure, all patients received 100 mg/d aspirin indefinitely and 75 mg/d clopidogrel for at least 12 months. A 12-lead ECG was obtained after the procedure and before discharge. Serum levels of creatine kinase and its MB isoenzyme were assessed 8, 12, and 24 hours after the procedure and thereafter if considered necessary.
Study End Point and Definitions
The primary end point of this trial was in-segment late loss at the 8-month angiographic follow-up. The secondary end points included 8-month angiographic outcomes of in-stent late loss and in-stent and in-segment restenosis at 8 months (defined as in-stent or in-segment stenosis of at least 50%). At 12 months, stent thrombosis, ischemiadriven target lesion revascularization, ischemia-driven target vessel revascularization, and major adverse cardiac events, including death resulting from any cause, MI, or ischemia-driven target lesion revascularization, were also assessed.
The diagnosis of DM was considered confirmed in all patients receiving active treatment with an oral hypoglycemic agent or insulin. For patients with a diagnosis of DM who were on a dietary therapy alone, enrollment in the trial required documentation of an abnormal blood glucose level after an overnight fast.
Angiographic success was defined as in-segment diameter stenosis Ͻ30% by quantitative coronary angiographic analysis. We defined MI as creatine kinase-MB elevation Ͼ3 times or creatine kinase elevation Ͼ2 times the upper normal limit with at least one of the following: ischemic symptoms, development of pathological Q waves, and ischemic ECG changes. Revascularization was defined as ischemia driven if there was stenosis of at least 50% of the diameter, as documented by a positive functional study, ischemic changes on an ECG, or ischemic symptoms, or, in the absence of documented ischemia, if there was stenosis of at least 70% as assessed by quantitative coronary analysis. Stent thrombosis was assessed according to the Academic Research Consortium definitions 16 and was classified by the timing of the event (acute, 0 to 24 hours; subacute, 0 to 30 days; late, Ͼ31 days).
Follow-Up
Repeat coronary angiography was mandatory at 8 months after stenting or earlier if indicated by clinical symptoms or evidence of myocardial ischemia. Clinical follow-up visits were scheduled at 30, 120, and 240 days and 1 year. At every visit, physical examination, ECG, cardiac events, and angina recurrence were monitored. At each participating center, patient data were recorded prospectively on standard case report forms and gathered in the central data management center (Asan Medical Center, Seoul, Korea). All adverse clinical events were adjudicated by an independent events committee blinded to the treatment groups.
Quantitative Coronary Angiographic Analysis
Coronary angiograms were obtained after intracoronary nitroglycerin administration. Procedure (baseline), postprocedure, and follow-up angiograms were submitted to the angiographic core analysis center (Asan Medical Center, Seoul, Korea). Digital angiograms were analyzed with an automated edge detection system (CASS II; Pie Medical, Maastricht, the Netherlands). Angiographic variables included absolute lesion length, stent length, reference vessel diameter, minimum lumen diameter, percent diameter stenosis, binary restenosis rate, acute gain, late loss, and the patterns of recurrent restenosis. Quantitative coronary angiographic measurements of target lesions were obtained for both the stented segment only (in stent) and the region including the stented segment and the margins 5 mm proximal and distal to the stent (in segment). In-segment late loss was calculated within the analysis segment itself but separately considering stented segment and the proximal and distal edges, taking the maximum change in minimum lumen diameter within those 3 segments, and applying it to this segment as a whole (maximal regional late loss method). 17 Patterns of angiographic restenosis were quantitatively assessed with the Mehran et al 18 classification.
Statistical Analysis
On the basis of results from previous trial, 10 we assumed an in-segment angiographic late loss of 0.43Ϯ0.45 mm in both arms. Calculation of the sample size was based on a margin of noninferiority for in-segment late loss of 0.15 mm, which is equal to 35% of an assumed mean late loss after the implantation of SES. Using a 1-sided 5% significance level, we estimated that 112 patients per group were needed to demonstrate noninferiority of EES with a statistical power of 80%. Expecting that Ϸ20% of the patients would not return for follow-up angiography, the total sample size was estimated to be 280 patients (140 patients per group). Analyses of the 2 groups were performed according to the intention-to-treat principle. Continuous variables are presented as meanϮSD or median (interquartile range) and compared by use of the Student unpaired t or Mann-Whitney U test. Categorical variables are presented as numbers or percentages and were compared by use of the 2 or Fisher exact test. The noninferiority hypothesis was assessed statistically with the use of a z test, by which 1-sided P values for noninferiority were calculated to compare differences between groups with margins of noninferiority, according the method of Chow and Liu. 19 All P values are 2 sided except those from noninferiority testing of the primary end point. A value of PϽ0.05 was considered to indicate a significant difference. All statistical analyses were performed with SAS version 9.1 (SAS Institute, Cary, NC). Table 1 shows the baseline clinical characteristics of study groups. Most of the clinical characteristics were similar between the 2 groups, although the SES group included significantly more men and acute MI. Table 2 shows the angiographic characteristics and procedural results. The 2 groups have similar anatomic and procedural characteristics. All stents were successfully implanted, and the angiographic success rate was 100% in all groups. The 2 groups were treated with similar stented lengths and the number of implanted stents per target lesion. Procedure-related non-Q-wave MI occurred similarly in both arms. In-hospital events, including Q-wave MI, emergency bypass surgery, or death, did not occur in either group.
Results
Baseline Characteristics of the Patients
Procedural Results and In-Hospital Outcomes
Angiographic Outcomes
Baseline and postprocedural quantitative coronary angiographic outcomes for the study groups are shown in (Tables I and II in the online-only Data  Supplement) . The results of quantitative coronary angiographic measurements at follow-up are shown in Table 3 . In-segment late loss of EES with maximal regional late loss method, the prespecified primary end point, was noninferior to that of the SES group (0.23Ϯ0.27 versus 0.37Ϯ0.52 mm; difference, Ϫ0.13 mm; 95% confidence interval, Ϫ0.25 to Ϫ0.02; upper 1-sided 95% confidence interval, Ϫ0.04; PϽ0.001 for noninferiority). In-segment late loss using the analysis segment late loss method was lower in EES versus SES patients (0.04Ϯ0.29 versus 0.18Ϯ0.51 mm; difference, Ϫ0.14 mm; 95% confidence interval, Ϫ0.25 to Ϫ0.03; Pϭ0.015). However, in-stent late loss (0.11Ϯ0.26 versus 0.19Ϯ0.49 mm; difference, Ϫ0.09 mm; 95% confidence interval, Ϫ0.19 to Ϫ0.02; Pϭ0.11) was not statistically different between the 2 groups. The rate of in-segment restenosis was 0.9% in the EES group and 6.5% in the SES group (Pϭ0.035). The in-stent restenosis rate was also lower in the EES than the SES group (0% versus 4.7%; Pϭ0.029). In patients with restenosis, the pattern of restenosis was not different between the 2 groups (Table 4) .
Clinical Outcomes
Major adverse cardiac events during follow-up are shown in Table 5 . A minimum 12-month clinical follow-up was performed in all patients. At 12 months, the incidence of individual and composite clinical outcomes did not differ significantly between the 2 groups. During 12 months, 1 stent thrombosis occurred in each group, which was subacute and probable stent thrombosis.
Discussion
The major finding of this study is that both EES and SES implantation showed favorable performance in diabetic patients. At 8 months, EES was noninferior to SES in reducing in-segment late loss and reduced angiographic restenosis in patients with DM and coronary artery disease.
Drug-eluting stents significantly reduced angiographic restenosis and cardiac events compared with bare metal stent in patients with DM. Compared with PES, SES showed promising efficacy in DM patients. 6 -10 Recently, newer DES has been a default strategy in routine practice in the treatment of coronary artery disease. In several randomized trials, EES showed superior efficacy over PES. [11] [12] [13] [14] Furthermore, intravascular analysis study showed that EES showed greater neointimal suppression without significant vessel expansion than PES in diabetic patients. 20 However, the relative efficacy of EES versus SES in diabetic patients has not been tested in a randomized study.
The present study shows that EES was noninferior to SES in reducing in-segment late loss and reduced angiographic restenosis. Although in-stent late loss may be served as a useful measure of the pure biological potency of DES and a more reliable predictor of restenosis, 21 we chose in-segment late loss as the primary end point because it is the most sensitive measure of the antiproliferative effectiveness of DES and accounts for the magnitude of lumen renarrowing that occurs at the margins of the stent. Because isolated stenoses at stent edges represent an increasingly greater proportion of target lesion revascularization events with a DES than a bare metal stent, in-segment measures might be a wise choice as a clinical event surrogate. 22 In this trial, EES was noninferior to SES for in-segment late loss with the maximal regional late loss method, the prespecified primary end point, and reduced in-segment late loss with the analysis segment late loss method. However, in-stent late loss was not statistically different between the 2 groups. In the previous studies, the late loss of the SES group in diabetic patients (in-stent late loss, 0.09 to 0.26 mm; in-segment late loss, 0.31 to 0.43 mm) was comparable to that observed in our study. 3, 9, 10, 23, 24 Late loss of the EES group of a nonselective population study using the analysis segment late loss method (in-stent late loss, 0.11 to 0.19 mm; insegment late loss, 0.06 to 0.10) was also comparable to that observed in our study. 12, 13, [25] [26] [27] Furthermore, a previous randomized trial comparing EES and SES also showed that in-stent late loss is lower in EES compared with SES (0.23Ϯ0.52 versus 0.28Ϯ0.57 mm; Pϭ0.08). 28 In addition, a randomized trial comparing EES and SES showed that the relative efficacy of EES was noninferior to SES in inhibiting in-segment late loss as a primary end point (0.10Ϯ0.36 versus 0.05Ϯ0.34 mm; upper 1-sided 95% confidence interval, 0.09; Pϭ0.023 for noninferiority). 29 Therefore, our findings demonstrated that the effectiveness of EES for neointimal suppression is extrapolated to the diabetic population.
We also observed that EES reduced in-stent and insegment restenosis compared with SES. In a previous study, restenosis rates of the SES group in a diabetic population (in-stent restenosis, 3.4% to 4.9%; in-segment restenosis, 4.0% to 8.8%) were comparable to those observed in our study. 3, 9, 10, 23, 24 However, in our EES group, the restenosis rates were numerically lower than those of the previous nonselective population study (in-stent restenosis rate, 2.3% to 3.8%; in-segment restenosis rate, 4.7% to 6.5%). 12, 13, [25] [26] [27] A recently published EES study comparing Japanese and American populations showed that intravascular ultrasoundguided aggressive post-balloon dilation and stent optimization reduced percent neointimal obstruction. 30 Although the exact mechanism underlying our findings remains unclear, 79% patients of the EES group were treated by intravascular ultrasound guidance, which partially explained the low restenosis rate in the EES group in our diabetic population. The reduced strut thickness (81 versus 140 m) and thinner polymer coating (7.6 versus 12.6 m), in conjunction with improved biocompatibility of the EES polymer, may favorably affect neointimal hyperplasia.
Although a noninferior rate of late loss and reduction in angiographic restenosis was shown in the EES versus the SES group, all clinical end points, including stent thrombosis, death, MI, ischemia-driven target lesion revascularization, ischemia-driven target vessel revascularization, and major adverse cardiac events, ie, composite outcomes of death, MI, or ischemia-driven target vessel revascularization, were not statistically different, which is supported by previous studies showing similar efficacy and safety for EES and SES. [31] [32] [33] Recently, a large-scale randomized clinical study (A Prospective, Randomized Trial of Everolimus-Eluting and SirolimusEluting Stents in Patients with Coronary Artery Disease [SORT-OUT IV]) which included Ͼ2600 patients across a wide range of lesion and patient complexity, also demonstrated a similar rate of the composite end point of major adverse cardiac events between the EES and SES groups (4.9% versus 5.2%). 33 
Study Limitations
The present study has limitations that should be addressed. First, in our study, in-segment late loss was calculated with the maximal regional late loss method. 17 However, a previous study showed that the clinical relevance of the maximal regional late loss was similar to that of the analysis segment late loss. 17 Second, the angiographic follow-up rate was lower than the protocol-based estimated rate. However, the number of patients undergoing angiographic follow-up provided a statistical power of 78% to demonstrate noninferiority of EES, which almost reached our protocol-based statistical power of 80%. Third, the SES group included significantly more men, a higher prevalence of acute MI, and marginally higher values of left ventricular ejection fraction. Therefore, we investigated whether these variables were effect modifiers and/or confounding effectors for in-segment and in-stent late loss. On linear regression adjusting for these variables, there were no significant interaction effects between groups and variables on both outcomes (PϾ0.10 for both). However, because of the low event number, we could not analyze the binary restenosis and clinical outcomes with adjustment of these variables. Finally, our study is a small angiographic outcomes study that was not powered for clinical outcomes. Therefore, our findings should be confirmed or rebutted by larger, longer-term follow-up study in diabetic patients.
Conclusion
The present study showed that EES implantation resulted in noninferior 8-month angiographic in-segment late loss and reduced 8-month angiographic restenosis rate without significant differences in MI, death, or stent thrombosis compared with SES implantation in patients with DM and coronary artery disease.
